Pretreatment of the peptide with matrix-metalloproteinase 9 (MMP9) led to uptake of the digested peptide by MCF-7 breast cancer cells, which secrete only a low level of MMP-917, whereas the untreated peptide was not cell-permeable (Fig. 9c). This evidence concerns the gene MMP9 and breast cancer.